Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GVB-2040
- Development stage
- Preclinical
- Lead developer
- Genvira Biosciences
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
01
Overview
GVB-2040 is a preclinical-stage cancer vaccine being developed by Genvira Biosciences. It utilizes a viral vector platform designed to deliver immune-stimulating genes and transcription factors that encode or target tumor-associated antigens (TAAs). The primary mechanism of action involves the activation of dendritic cells (DCs) to trigger a robust anti-tumor immune response. As of early 2024, the program has demonstrated validation in cell line data and is being investigated for various oncological indications. The intellectual property for this asset is 100% owned by Genvira Biosciences under patent filing PCT/CA2025/R00415.
Beyond the preview
Go deeper on GVB-2040.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GVB-2040.